JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.
在星期四，bluebird bio報告第三季度每股收益虧損31美分，而去年同期每股虧損80美分，超過了預期虧損36美分。
The gene therapy company reported sales of $10.6 million, down from $12.39 million, missing the consensus of $18.1 million.
這家基因療法公司報告銷售額爲1060萬美元，低於1239萬美元，未達到預期的1810萬美元。
The company's cash, cash equivalents, and restricted cash balance were approximately $118.7 million, which is expected to provide a cash runway into the first quarter of 2025.
該公司的現金、現金等價物和受限現金餘額約爲11870萬美元，預計將提供現金支持至2025年第一季度。
Also Read: Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
另請閱讀：圍繞bluebird bio基因療法的癌症風險增加擔憂
The company anticipates quarterly cash flow break-even in the second half of 2025, assuming it scales to approximately 40 drug product deliveries per quarter and obtains additional cash resources to extend its runway.
公司預計在2025年下半年實現季度現金流盈虧平衡，假設其將規模擴大至每季度約40個藥品交付，並獲得額外的現金資源以延長其現金支持時間。
JP Morgan downgraded Bluebird after the third-quarter results. The analyst notes a reduced cash runway to "into 1Q25" from "into 2Q25."
摩根大通在第三季度業績後下調了bluebird bio的評級。分析師指出現金支持延長到"進入2025年第一季度"，而不是"進入2025年第二季度"。
JP Morgan highlights that Bluebird did achieve the milestone of its first Lyfgenia infusion during the quarter (and revenue recognition) and continues to increase the pace of patient starts (cell collections) across its portfolio but is doing so against a backdrop of continued negative gross margins.
摩根大通強調，在本季度達到了第一次Lyfgenia輸注的里程碑（以及營業收入確認），並繼續增加患者開始治療（電芯收集）的速度，但面對持續的負利潤率背景展開這一做法。
- 57 patient starts completed to date in 2024 (35 Zynteglo, 17 Lyfgenia, 5 Skysona).
- Seventeen additional starts are scheduled through the remainder of 2024.
- 截至2024年迄今已完成57例患者開始治療（35例Zynteglo，17例Lyfgenia，5例Skysona）。
- 到2024年底，將安排額外進行十七場比賽。
"Altogether presenting few avenues to emerge from remaining a going concern," the analyst says. JP Morgan has downgraded from Neutral to Underweight.
「總體而言，分析師表示幾乎沒有任何途徑從繼續存在的狀態中脫身。」 JP摩根已將評級從中立下調至減持。
The analyst writes that the proxy vote did not gather enough support to approve a reverse stock split and increase the number of shares available for issuance. This outcome effectively eliminates equity financing as an option for raising capital.
分析師寫道，代理表決未獲得足夠支持來批准股票拆分並增加可用於發行的股份數量。這一結果有效地排除了股權融資作爲籌集資本的選項。
In September, Bluebird bio implemented a restructuring to optimize its cost structure and enable quarterly cash flow break-even in the second half of 2025.
今年9月，bluebird bio實施了一項重組，以優化其成本結構，並使2025年下半年實現季度現金流達到盈虧平衡。
Price Action: BLUE stock is down 11.2% at $0.32 at last check Friday.
價格走勢：BLUE股票在上週五最後一次交易時下跌了11.2％，報0.32美元。
Photo by Ground Picture on Shutterstock
來自Shutterstock的Ground Picture拍攝的照片
- Mullen Drives Into Government Sector With Electric Bollinger B4 Trucks
- Mullen通過電動Bollinger B4卡車進軍政府板塊。
譯文內容由第三人軟體翻譯。
